LifeTime started as the shared vision of leading scientists (Founding Members) at over 50 renowned organizations across Europe, who selected 18 partners to submit the proposal. The LifeTime EU grant consortium received funding from Horizon 2020 for a one year Coordination and Support Action (CSA) to prepare a roadmap for a large scale research initiative. It consisted of 17 Beneficiaries and 3 Linked Third Parties in 15 countries.
Beyond these partners, numerous institutions joined the LifeTime CSA as Associated partners. They are all listed below.
Over 80 companies of various sizes and from different sectors (single-cell technologies, pharmaceuticals, medical diagnostics, biotechnologies, imaging technologies, IT and data sciences) have supported LifeTime preparatory action.
LifeTime is coordinated by Nikolaus Rajewsky at the Max Delbrück Center in Berlin (Germany) and Geneviève Almouzni at the Institut Curie in Paris (France).
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Department of Genomics, Stem Cell Biology & Regenerative Medicine – Institute of Molecular Biology of the University of Innsbruck
- Institute of Molecular Biotechnology (IMBA)
- Medical University of Vienna
- Biothèque Wallonie Bruxelles (BWB)
- de Duve Institute
- Ghent university
- GIGA Institute – University of Liège
- imec
- KU Leuven
- Université libre de Bruxelles
- VIB
- Génome Québec
- Czech Technical University in Prague
- Aarhus University
- University of Eastern Finland
- University of Helsinki, Institute for Molecular Medicine Finland
- University of Oulu, Faculty of Biochemistry and Molecular Medicine
- Cordeliers Research Center
- French National Centre for Scientific Research (CNRS)
- Imagine Institute of Genetic Diseases
- INRIA
- INSERM
- Institut Curie
- Institut Pasteur
- Mines ParisTech
- Montpellier Cancer Institute (ICM)
- Paris Saclay
- Sorbonne Université
- UMR INRA-ENVA BDR – Biologie du Développement et Reproduction / UMR INRA-ENVA-UVSQ Biologie de la Reproduction Environnement, Epigénétique et Développement
- University of Montpellier
- Charité
- CISPA Helmholtz Center for Information Security
- European Molecular Biology Laboratory (EMBL) in Heidelberg
- German Cancer Research Center (DKFZ)
- German Center for Neurodegenerative Diseases (DZNE)
- Helmholtz Centre for Infection Research (HZI) / Helmholtz Institute for RNA-based Infection Research (HIRI)
- Helmholtz Zentrum München
- HI-STEM gGmbH – Heidelberg Institute for Stem Cell Technology and Experimental Medicine
- Institute of Neuropathology, University Hospital Freiburg
- Leibniz Institute on Aging – Fritz Lipmann Institute (FLI)
- Max Delbrück Center for Molecular Medicine
- Max Planck Institute for Biology of Ageing
- Max Planck Institute for Molecular Genetics
- Max Planck Institute of Immunobiology and Epigenetics
- Saarland University
- Technical University of Munich
- Universitätsklinikum Aachen
- University Medical Centre Hamburg-Eppendorf
- Biomedical Research Foundation of the Academy of Athens
- Foundation for Research and Technology Hellas
- Technion-IIT
- Tel-Aviv University
- The Hebrew University of Jerusalem
- Weizmann Institute of Science
- Dipartimento di Fisica, Università di Napoli “Federico II”
- Alma Mater Studiorum – Università di Bologna
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento
- Department of Experimental Medicine, Sapienza University of Rome
- Fondazione Istituto FIRC di Oncologia Molecolare
- Human Technopole
- Institute for Biomedical Technologies – Italian National Research Council
- Institute of Photonics and Nanotechnologies – Italian National Research Council
- Istituto Europeo di Oncologia s. r. l.
- University of Milan
- University of Milano-Bicocca
- University of Modena and Reggio Emilia – Department of Life Sciences (DSV)
- University of Padova
- University of Torino (incl. Molecular Biotechnology Centre)
- University of Trieste – Department of Life Sciences (DSV)
- Luxembourg Centre for Systems Biomedicine
- Hubrecht Institute/Royal Netherlands Academy of Arts and Sciences
- Radboud University Medical Center
- The Netherlands Cancer Institute
- UMC Utrecht
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences
- Institute of Bioorganic Chemistry of the Polish Academy of Sciences
- International Institute of Molecular and Cell Biology in Warsaw
- Medical University of Gdansk
- Nencki Institute of Experimental Biology, Polish Academy of Sciences
- Instituto Gulbenkian de Ciência
- Iuliu Haţieganu University of Medicine and Pharmacy Cluj‐Napoca
- University of Ljubljana, Faculty of Computer and Information Science
- Barcelona Supercomputing Center
- Centro de Biología Molecular Severo Ochoa (CSIC-UAM)
- Centre de Medicina Regenerativa de Barcelona
- Centre for Genomic Regulation (CRG)
- Centro Andaluz de Biología del Desarrollo (CABD)
- Fundación Privada Instituto de Investigación Oncologica Vall d’Hebron – VHIO
- IMDEA Food Institute
- Institute for Research in Biomedicine – IRB Barcelona
- Josep Carreras Leukaemia Research Institute
- Molecular Biology Institute of Barcelona (IBMB-CSIC)
- The Institute for Bioengineering of Catalonia (IBEC)
- Universitat Pompeu Fabra
- Vall d’Hebron Institute of Research (VHIR)
- Karolinska Institutet
- Biozentrum University of Basel
- Friedrich Miescher Institute for Biomedical Research
- Institute of Molecular Biology and Genetics of National Academy of Science of Ukraine
- Babraham Institute
- Dementia Research Institute UK
- EMBL European Bioinformatics Institute at Hinxton
- Francis Crick Institute
- MRC Human Genetics Unit, University of Edinburgh
- MRC London Institute of Medical Sciences
The LifeTime Consortium includes the preeminent European laboratories developing multi-omic and bioimaging technologies, the institutions required to develop the computational technologies and infrastructure, world-renowned laboratories in the area of organoids to push the frontier of personalised disease models, bioethicists and a core group of leading clinician scientists.
LifeTime’s vision and objectives align with current European clinical needs. Many of the involved institutions include or are linked to translational/clinical research facilities and hospitals, ensuring that LifeTime discoveries can be rapidly translated into clinical practice. The diversity, excellence, and interdisciplinary connectedness of its members places LifeTime in a unique position to galvanise the relevant expertise and stakeholders required to address the major science and technology objectives.